References
1. Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420-429. doi: 1010.1053/j.gastro.2017.04.022[Links]
2. Kalali B, Formichella L, Gerhard M. Diagnosis of Helicobacter pylori: Changes towards the Future. Diseases. 2015;3(3):122-135. doi:10.3390/diseases3030122[Links]
3. Malfertheiner P, Megraud F, O'Morain C, et al. Management of helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6-30. doi:10.1136/gutjnl-2016-312288[Links]
4. Hu Q, Zhang Y, Zhang X, Fu K. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: A review of current diagnosis and management. Biomark Res. 2016;4(1):1-9. doi:10.1186/s40364-016-0068-1[Links]
5. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-1367. doi:10.1136/gutjnl-2015-309252[Links]
6. Gisbert JP, Molina-Infante J, Amador J, et al. IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterol Hepatol. 2016;39(10):697-721. doi:10.1016/j.gastrohep.2016.05.003[Links]
7. Otero RW, Gómez ZM, Otero PL, Trespalacios RA. Helicobacter pylori: ¿cómo se trata en el 2018? Rev Gastroenterol Peru. 2018;38(1):54-63.[Links]
8. Molina-Infante J, Shiotani A. Practical Aspects in Choosing a Helicobacter pylori Therapy. Gastroenterol Clin North Am. 2015;44(3):519-535. doi:10.1016/j.gtc.2015.05.004[Links]
9. Camargo MC, García A, Riquelme A, et al. Systematic Review in Latin America. Am J Gastroenterol. 2014;109(4):485-495. doi:10.1038/ajg.2014.24.The[Links]
10. Liao J, Zheng Q, Liang X, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013;18(5):373-377. doi:10.1111/hel.12052[Links]
11. Liang X, Xu X, Zheng Q, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11(7):802-807.e1. doi:10.1016/j.cgh.2013.01.008[Links]
12. Henao Riveros SC, Quiroga A, Martínez Marín JD, Otero Regino W. Resistencia primaria a la claritromicina en aislamientos de Helicobacter pylori. Rev colomb gastroenterol. 2009;24(2):110-114. doi: ISSN: 0120-9957[Links]
13. Arévalo A, Otero W, Trespalacios AA. Helicobacter pylori: resistencia múltiple en pacientes de Bogotá, Colombia. Biomédica. 2019;39:125-134. https://www.revistabiomedica.org/index.php/biomedica/article/view/4437/4121.[Links]
14. Trespalacios-Rangél AA, Otero W, Arévalo-Galvis A, Poutou-Piñales RA, Rimbara E, Graham DY. Surveillance of levofloxacin resistance in helicobacter pylori isolates in Bogotá-Colombia (2009-2014). PLoS One. 2016;11(7):1-10. doi:10.1371/journal.pone.0160007[Links]
15. Graham DY, Shiotani A. Newer concepts regarding resistance in the treatment Helicobacter pylori infections. Nat Clin Pr Gastroenterol Hepatol. 2008;5(6):321-331. doi:10.1038/ncpgasthep1138.Newer[Links]
16. Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22(4):1-13. doi:10.1111/hel.12392[Links]
17. Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: High-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28(7):868-877. doi:10.1111/j.1365-2036.2008.03807.x[Links]
18. Yu L, Luo L, Long X, et al. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial. Helicobacter. 2019;24(4):1-7. doi:10.1111/hel.12596[Links]
19. Hu J. Optimized high-dose amoxicillin dual therapies fail to achieve high cure rates in China. Saudi J Gastroenterol. 2017;23(5):275-280.[Links]
20. Bayerdorffer E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology. 1995;108(5):1412-1417. doi:10.1016/0016-5085(95)90689-4[Links]
21. Bayerdorffer E, Rudolph B, Neubauer A, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet. 1995;345(8965):1591-1594. doi:10.1016/S0140-6736(95)90113-2[Links]
22. Malfertheiner P. Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut. 1997;41(1):8-13. doi:10.1136/gut.41.1.8[Links]
23. Graham D, Lu H, Shiotani A. Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now? Saudi J Gastroenterol. 2017;23(5):265-267. doi:10.4103/sjg.SJG_292_17[Links]
24. Yang J, Zhang Y, Fan L, et al. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori. Am J Gastroenterol. 2019;114(3):437-445. doi:10.14309/ajg.0000000000000132[Links]
25. Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13(5):895-905.e5. doi:10.1016/j.cgh.2014.10.036[Links]
26. Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut. 1998;43(SUPPL. 1):56-60. doi:10.1136/gut.43.2008.s56[Links]
27. El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14(4):447-460. doi:10.1080/17425255.2018.1461835[Links]
28. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103-113. doi:10.1016/j.clpt.2005.10.002[Links]
29. Deshpande N, V. S, Ravi RK, et al. Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors. Meta Gene. 2016;9:159-164. doi:10.1016/j.mgene.2016.06.004[Links]
30. Arévalo Galvis A, Trespalacios Rangel AA, Otero Regino W. Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy. Helicobacter. 2019;24(3):1-11. doi:10.1111/hel.12574[Links]
31. Suzuki S, Gotoda T, Kusano C, et al. day vonoprazan and low- dose amoxicillin dual therapy as first- line Helicobacter pylori treatment: a multicentre randomised trial in Japan. 2020:1-8. doi:10.1136/gutjnl-2019-319954[Links]
32. Dixon MF, Genta RM, Yardley HJ et al. Classification and grading of gastritis. The updated Sydney System. Am J Surg Pathol. 1996;20(10):1161-1181.[Links]
33. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: A tutorial. Dig Liver Dis. 2008;40(8):650-658. doi:10.1016/j.dld.2008.02.030[Links]
34. Otero R. W, Trespalacios R. AA, Otero P. L, et al. Guía de práctica clínica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. Rev Colomb Gastroenterol. 2015;30:17-33.[Links]
35. Farmalatina. Prueba Rápida OnSite H. pylori Ag -Casete (Muestra Fecal). En: https://www.farmalatina.cl/wp-content/uploads/2020/04/PI-R0192C-Spanish-Rev-H.pylori.pdf[Links]
36. Tang HL, Li Y, Hu YF, Xie HG, Zhai S Di. Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical Trials. PLoS One. 2013;8(4). doi:10.1371/journal.pone.0062162[Links]
37. Gao CP, Zhang D, Zhang T, et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter. 2020;25(4):1-8. doi:10.1111/hel.12692[Links]
38. Tai WC, Liang CM, Kuo CM, et al. A 14 day esomeprazole- And amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019;74(6):1718-1724. doi:10.1093/jac/dkz046[Links]
39. Zhu YJ, Zhang Y, Wang TY, et al. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Therap Adv Gastroenterol. 2020;13:1-12. doi:10.1177/1756284820937115[Links]
40. Pan KF, Zhang L, Gerhard M, et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: Baseline results and factors affecting the eradication. Gut. 2016;65(1):9-18. doi:10.1136/gutjnl-2015-309197[Links]
41. Itskoviz D, Boltin D, Leibovitzh H, et al. Smoking increases the likelihood of Helicobacter pylori treatment failure. Dig Liver Dis. 2017;49(7):764-768. doi:10.1016/j.dld.2017.03.010[Links]
42. Suzuki T, Matsuo K, Ito H, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006;119(3):217-224. doi:10.1016/j.amjmed.2005.10.003[Links]
